

Sanofi sells manufacturing site in Japan to CDMO Adragos Pharma

14 October 2022 | News

The Kawagoe site is led by a highly experienced site leadership team and boasts a very well- trained workforce



Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, has signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan.

Furthermore, Adragos Pharma will introduce new customers to the manufacturing site from Europe, North America as well as the domestic Japanese market. Their second investment in the region, Adragos Pharma will now rank among the Top 3 largest pure-play CDMOs in Japan.

Sanofi and Adragos Pharma signed definitive agreements for the transfer of ownership of one of Sanofi's manufacturing sites in Japan. The site, located in Kawagoe, Japan, has more than 50 years of pharmaceutical manufacturing history.

Under Sanofi, the site manufactured oral solids, sterile liquids, and conducted packing, visual inspection, and retesting services for the Japanese and Asian markets. Adragos Pharma will continue to manufacture for Sanofi under a long-term supply agreement and become its strategic partner for the Japanese market. Japan is one of Adragos Pharma's three core markets.

The Kawagoe site is led by a highly experienced site leadership team and boasts a very well- trained workforce, who will all remain at the site. Adragos Pharma intends to further expand the site's services and capabilities for Sanofi and its future customers, opening production capabilities in the Japanese market and supporting its mission to facilitate access to affordable, high-quality medication.